Invitation: RLS Global AB provides livestream strategy update focusing on the global collaboration with ConvaTec Ltd

Invitation: RLS Global AB provides livestream strategy update focusing on the global collaboration with ConvaTec Ltd

RLS long term vision is to be a leading research driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as burns and dermatology. In order to maximize our patient reach, RLS intends to work with partners to commercialize its products globally. RLS is confident in the company’s platform technology and its unique features and what this can bring to patients around the world.

Thursday, October 14th at 09:00 am CET, RLS will present a strategy update focusing on the company’s platform, the recently established global collaboration with ConvaTec Ltd and new research project within the company. The presentation is followed by a question-and-answer session led by Redeye’s analyst Erik Nordström.

RLS CEO, Karin Fischer, will lead the presentation together with Susanne Olausson, CTO, and Magnus Nolmark, COO. Additional participant is also Roland Frösing, MD, PhD and board member.

The presentation will be held in English.

For more information and registration: Click here


Karin Fischer, CEO
Telephone: +46 702 48 46 51

Eva Jagenheim, CFO
Telephone: +46 730 23 13 57

Welcome to RLS Global Newsletter No. 2 2021

Newsletter No. 2, 2021

ChloraSolv01 study soon to be published in Journal of Wound Care

As communicated previously, RLS has submitted the clinical trial ChloraSolv01 to high ranked scientific journals to be reviewed and evaluated for publication. It is now confirmed that Journal of Wound Care has approved the data and will publish the publication in the issue of July 2021.

Journal of Wound Care is one of the most established magazines in the wound management community and it is a great recognition to ChloraSolv01 and the clinical outcome. The publication has been reviewed by an external editorial board and accepted. The article will have an open access, so anyone can get access to the results when published.

Highlights from the study were presented at the EWMA 2020 virtual conference. It was found that after only six treatments/debridements with ChloraSolv, 71,4% of the patients had a reduction of 50% or more of devitalized tissue. The study showed low pain score in general. The reduction of devitalized tissue was an average of -72,7%. At the same time, the wound size reduction was -30,9%.

Ease of use and time are two very important key components if the aim is to establish a new technology as a standard of care. In the ChloraSolv study these areas were evaluated by the care givers. The tables below summarize the questions and the percentage outcome:














An overall evaluation by the investigators/nurses showed that 68,9% of the responders agree that ChloraSolv debridement gel makes the debridement easier than previously used debriding treatments, whereas only 3,8% do not agree.

Also to be mentioned, the investigation showed that debridement in conjunction with the use of ChoraSolv was well tolerated and efficient. Most of the investigators/nurses found that debridement was easier performed with ChloraSolv than treatments previously used.

It is a very strong recognition that ChloraSolv has been accepted by Journal of Wound Care and will be published within the next few months. Journal of Wound Care is one of the most respected journals in the wound management community.

Finally, I would like to welcome you to ChloraSolv Academy. ChloraSolv Academy is a platform and forum where RLS gathers stakeholders in advanced wound care with the aim to sharing knowledge, experience and clinical data related to research for patients with difficult to heal wounds. Our focus area is good wound debridement required to support effective wound healing. At present, the website is available in Swedish:

ChloraSolv Academy – Allt du behöver veta om debridering

I hope you will take some time and review all the information available at ChloraSolv Academy.


Karin Fischer
CEO RLS Global

Welcome to RLS Global Newsletter No. 1 2021

Newsletter No. 1, 2021

Interaction within the health care sector is essential

It is exciting to kick off a new year for RLS Global. 2020 was a different year with a lot of challenges but also new opportunities. The life science business is traditional when it comes to establish long term relationships with current and new stakeholders. Interactions are important to share experience and know-how. Congresses, symposiums, trainings at the clinics, exhibitions – the real life meetings are very essential to the business.

2020 was the year when all these meeting points closed down. Skype, Teams and Zoom became the new arena to meet, and educational webinars were developed and shared through different communication channels. Interaction within the health care sector is essential to drive knowledge, innovation and the science forward.

RLS will continue to drive the market penetration of ChloraSolv in 2021. Several projects are initiated to achieve reimbursement in strategic prioritized markets in Europe. The objective is to involve key opinion leaders to evaluate the technology and collect local data which will support the pricing strategy. RLS is working with experienced consultants in these countries whom have the right network in place. Long term reimbursement is key to secure a sustainable business. Also, the projects that are established in the UK and Denmark will continue as soon as the clinics open up again.

RLS conducts an advisory board meeting early February, which is a joint cooperation with EWMA (European Wound Management Association). Clinicians from five different countries will attend (Germany, UK, the Netherlands, Sweden and Denmark). Key opinion leaders from Sweden with experience of ChloraSolv will attend the meeting and share know-how and experience. The objective is to seek advice on the prerequisites for a successful market introduction, clinical issues to consider including advice on additional clincial data.

RLS is actively working with new biofilm models to further evaluate effects on biofilm with our unique technology. According to the literature – all chronic wounds are affected by biofilm. Biofilm is one of the main reasons the wound ends up as chronic and has a negative impact on the wound healing process.

I want to take the opportunity to share another excellent patient case treated with ChloraSolv. The duration of the wound was more than six months. The patient was treated with ChloraSolv during six weeks with this amazing result!

Focus areas for 2021 is, as earlier communicated, to establish a regional/global partnership for ChloraSolv. It is also the year when initiatives are taken for new indications based on RLS technical platform. RLS will take several steps forward for the US market and it is the year when the industry will meet customers and patients in real life again.

2021 – bring it on!


Karin Fischer
CEO RLS Global